Aurobindo Pharma gets MoEFCC nod for Andhra Pradesh plant expansion

The Rs 250 crore expansion project by Aurobindo Pharma is expected to generate jobs for 600 people directly and 120 indirectly.

Hyderabad: The Rs 250-crore expansion plan of Aurobindo Pharma's manufacturing facility in Srikakulam district of Andhra Pradesh has been accorded environmental clearance by the Ministry of Environment, Forests and Climate Change.

The plan was for increasing the production capacity of for bulk drugs and intermediates manufacturing unit from 583.31 TPM (tonnes per month) to 1518.3 TPM, a press release said here Monday.

Read Also: Aurobindo Pharma recalls 88600 vials of Lidocaine injections from US

The project involves also installation of a captive power plant of 8.85 MW, the release said.

The project is expected to create jobs for 600 people directly and 120 indirectly, it said.

Read Also: Lupin, Aurobindo Pharma recalls multiple lots of BP drug including VALSARTAN

The estimated cost for the expansion is Rs 250 crore. The total capital cost earmarked for environmental pollution control measures is Rs 32.77 crore and the recurring cost (operations and maintenance) would be about Rs 8.84 crore per annum, it said.

Aurobindo Pharma is headquartered in HITEC City, Hyderabad, India. The company manufactures generic pharmaceuticals and active pharmaceutical ingredients. The company’s area of activity includes six major therapeutic/product areas: antibiotics, anti-retroviral, cardiovascular products, central nervous system products, gastroenterological, and anti-allergic. The company markets these products in over 125 countries. Its marketing partners include AstraZeneca and Pfizer.

Also Read: Aurobindo Pharma acquires 7 oncology products worth over Rs 2100 crore from US firm